文献速递认知障碍与痴呆

持续气道正压通气与阻塞性睡眠呼吸暂停成人认知障碍:系统综述

Positive Airway Pressure and Cognitive Disorders in Adults With Obstructive Sleep Apnea: A Systematic Review of the Literature.
PubMed 文献 · Neurology · 2022-07-25

该系统综述检索MEDLINE、EMBASE、Scopus和CINAHL截至2021年5月的文献,纳入11项研究(3项临床试验和8项观察性研究),其中96%参与者患有阻塞性睡眠呼吸暂停(n=60,840),9%有基线认知障碍(n=5,826)。11项研究中有9项报告持续气道正压通气(PAP)治疗对轻度认知障碍(MCI)和阿尔茨海默病(AD)发病率有保护作用,如延迟MCI发病年龄、降低MCI或AD发病率、减缓认知下降或向AD进展。

要点

  • 11项研究中9项报告PAP治疗对MCI和AD发病率有保护作用。
  • 96%参与者患有OSA(n=60,840),9%有基线认知障碍(n=5,826)。
  • 43,970人接受PAP治疗,16,400人未治疗或处于安慰剂组。

核心结论

  • 这些发现提示OSA作为认知下降的可改变危险因素可能发挥作用。
  • 未来研究应基于本综述,聚焦PAP干预作为减轻认知障碍和认知下降发病率的潜在手段,尤其是在现有文献中代表性和研究不足的种族群体中。

研究设计与样本

  • 系统综述,检索MEDLINE、EMBASE、Scopus和CINAHL截至2021年5月的文献。
  • 纳入11项研究(3项临床试验和8项观察性研究)。
  • 纳入标准为研究PAP治疗对≥40岁诊断为OSA个体认知障碍发病率的影响,以及对已有认知障碍和OSA患者认知下降进展的影响。

主要发现

  • 96%参与者患有OSA(n=60,840),9%有基线认知障碍(MCI或AD)(n=5,826)。
  • 43,970名参与者接受PAP治疗,16,400名未治疗或处于安慰剂组。
  • 11项研究中有9项报告PAP治疗对MCI和AD发病率有保护作用,如延迟MCI发病年龄、降低MCI或AD发病率、减缓认知下降或向AD进展。

局限性

  • 未来研究应基于本综述,聚焦PAP干预作为减轻认知障碍和认知下降发病率的潜在手段,尤其是在现有文献中代表性和研究不足的种族群体中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Alzheimer disease (AD) and other forms of dementia represent a rising global public health crisis. Because effective treatments to prevent, cure, or slow progression of dementia are unavailable, identification of treatable risk factors that increase dementia risk such as obstructive sleep apnea (OSA) could offer promising means to modify dementia occurrence or severity. Here, we systematically reviewed the impact of positive airway pressure (PAP) therapy on the incidence of cognitive disorders and cognitive decline among middle-aged and older adults with OSA. METHODS: We performed a systematic search of MEDLINE, EMBASE, Scopus, and CINAHL before May 2021 to identify articles that focused on associations between PAP therapy use and cognitive disorders. We included studies that examined the effects of PAP treatment on (1) the incidence of cognitive disorders among individuals ≥40 years of age diagnosed with OSA and (2) the progression of cognitive decline among people with preexisting cognitive disorders and OSA. RESULTS: We identified 11 studies (3 clinical trials and 8 observational studies). In these studies, 96% participants had OSA (n = 60,840) and 9% had baseline cognitive impairment (mild cognitive impairment [MCI] or AD) (n=5,826). Of all study participants, 43,970 obtained PAP therapy, and 16,400 were untreated or in a placebo group. Nine out of 11 studies reported a protective effect of PAP therapy on MCI and AD incidence, e.g., delayed age at MCI onset, reduced MCI or AD incidence, slower cognitive decline, or progression to AD. DISCUSSION: These findings suggest a role for OSA as a modifiable risk factor for cognitive decline. Identification of modifiable risk factors is imperative for alleviating the impact of cognitive disorders on aging adults and their family members. Future research should build on this review and focus on PAP interventions as a potential means to alleviate the incidence of cognitive disorders and cognitive decline, particularly among ethnoracial groups who have been underrepresented and underinvestigated in the extant literature.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Shieu MM, Zaheed AB, Shannon C, et al. Positive Airway Pressure and Cognitive Disorders in Adults With Obstructive Sleep Apnea: A Systematic Review of the Literature. Neurology. 2022. PMID: 35523585. doi:10.1212/WNL.0000000000200383

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。